PP
ALLO icon

PDT Partners’s Allogene Therapeutics ALLO Stock Holding History

PDT Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-85,610
Closed -$199K – 716
2024
Q2 		$199K Sell
85,610
-103,418
-55% -$305K 0.02% 606
2024
Q1 		$845K Buy
189,028
+173,084
+1,086% +$722K 0.08% 366
2023
Q4 		$51.2K Hold
15,944
– – 0.01% 527
2023
Q3 		$50.5K Buy
+15,944
New +$69.9K 0.01% 569
2022
Q4 		– Sell
-112,701
Closed -$1.22M – 620
2022
Q3 		$1.22M Sell
112,701
-85,018
-43% -$1.16M 0.18% 166
2022
Q2 		$2.25M Sell
197,719
-43,873
-18% -$389K 0.2% 145
2022
Q1 		$2.2M Buy
241,592
+55,510
+30% +$578K 0.19% 149
2021
Q4 		$2.78M Buy
186,082
+127,355
+217% +$2.25M 0.21% 170
2021
Q3 		$1.51M Sell
58,727
-105,101
-64% -$2.5M 0.11% 288
2021
Q2 		$4.27M Buy
163,828
+82,563
+102% +$2.35M 0.28% 156
2021
Q1 		$2.87M Sell
81,265
-52,476
-39% -$1.77M 0.21% 206
2020
Q4 		$3.38M Buy
133,741
+36,798
+38% +$1.2M 0.23% 187
2020
Q3 		$3.66M Buy
+96,943
New +$3.65M 0.24% 158
2020
Q1 		– Sell
-15,640
Closed -$406K – 648
2019
Q4 		$406K Buy
+15,640
New +$431K 0.03% 464

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PDT Partners's ALLO Position: Q3 2024 in Review

PDT Partners sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 85,610 shares — an estimated $199K sold.

PDT Partners first reported a position in ALLO in Q4 2019 and held it in 14 quarters. The position peaked at $4.27M in Q2 2021. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • PDT Partners reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • PDT Partners sold 85,610 Allogene Therapeutics shares in Q3 2024, an estimated $199K.
  • PDT Partners first reported a position in Allogene Therapeutics in Q4 2019 and held it in 14 quarters.
  • PDT Partners's Allogene Therapeutics position peaked at $4.27M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on PDT Partners's 13F filing for Q3 2024, filed 14 Nov 2024.